Bommer Wolfgang, Eibl Hans J, Engel Kirsten R, Kuhlencord Armin, Sindermann Herbert, Sundar Sham, Zappel Hildegard
Institut für Allgemeine Hygiene der Universität Göttingen/Tropenmedizinisches Beratungszentrum, Göttingen, Deutschland.
Wien Klin Wochenschr. 2004;116 Suppl 4:24-9.
Hexadecylphosphocholine (HDPC, Miltefosine, Impavido) was synthesized at the Max-Planck-Institut für Biophysikalische Chemie in Göttingen, Germany and successfully used for the therapy of cancer metastases. At the Institute of General and Tropical Hygiene of Göttingen University the antiparasitic efficacy--earlier mentioned by Croft et al. (1987)--could be established for the first time in animals after oral administration. In India Impavido has been recently registered for the treatment of visceral leishmaniasis as the first oral medication in this indication. Clinical studies in India--actually a phase IV study is running--and Columbia (cutaneous leishmaniosis) demonstrated the excellent efficacy of this oral treatment also in patients with Antimon resistance. The cure rates are above 90% with low side effects (Impavido twice 50 mg capsules daily over 28 days).
十六烷基磷酸胆碱（HDPC，米替福新，Impavido）由德国哥廷根的马克斯 - 普朗克生物物理化学研究所合成，并成功用于癌症转移的治疗。在哥廷根大学普通与热带卫生研究所，抗寄生虫疗效——此前由克罗夫特等人（1987年）提及——首次在动物口服给药后得到证实。在印度，Impavido最近已注册用于治疗内脏利什曼病，是该适应症的首个口服药物。印度的临床研究——实际上一项IV期研究正在进行——以及哥伦比亚（皮肤利什曼病）的研究表明，这种口服治疗对锑剂耐药患者也具有出色疗效。治愈率超过90%，副作用低（每日两次，每次50毫克胶囊，持续28天）。
